Stifel Nicolaus Says That Rhythm Pharmaceuticals (RYTM) Has $36 Stock Target

September 15, 2018 - By Christine McCrea

Why Has Stifel Nicolaus Given Rhythm Pharmaceuticals (RYTM) a $36 Price Target

In an analyst note issued to clients on Friday morning, Stifel Nicolaus analyst has today began coverage for Rhythm Pharmaceuticals (RYTM) shares with a “Hold” rating. The price target is exactly $36.

The stock decreased 3.31% or $1.04 during the last trading session, reaching $30.36. About 102,661 shares traded. Rhythm Pharmaceuticals, Inc. (RYTM) has 0.00% since September 15, 2017 and is . It has underperformed by 15.62% the S&P500.

Analysts await Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to report earnings on November, 13. They expect $-0.38 EPS, up 78.65 % or $1.40 from last year’s $-1.78 per share. After $-0.52 actual EPS reported by Rhythm Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -26.92 % EPS growth.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $1.04 billion. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More news for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) were recently published by:, which released: “New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and …” on August 20, 2018.‘s article titled: “Premarket analyst action – healthcare” and published on September 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.